Thursday 05 September | 13:00 - 14:00
Lunchtime Symposia
Thursday 05 September | 13:00 - 14:00
The Great Fluid Debate: Reviewing Treatment Outcome Goals for the Wet AMD Patient
Moderator(s): S. Wolf Switzerland F.G. Holz Germany
S. Wolf Switzerland F.G. Holz Germany Welcome, opening audience response system questions
F.G. Holz Germany Review of EURETINA delegate survey data to assess baseline trends
S. Wolf Switzerland Keys to accurately and consistently diagnosing fluid levels with multi-modal imaging
M. Zinkernagel Switzerland Debate Side #1: Our goal with AMD patients should be to eliminate all retinal fluid to maximize outcomes
P. Dugel USA Recent OCT fluid analyses and their clinical implications
R. Tadayoni France Debate Side #2: AMD patients can tolerate a small amount of SRF with no impact on visual outcome and it may be helpful in some patients
S. Wolf Switzerland F.G. Holz Germany Panel Discussion: Why is “fluid-free” vs “residual fluid” a difficult outcome decision to make and what future diagnostics and treatments may help both sides of this debate?
Supported by:
Superior Visualization with Swept Source OCT and OCT Angiography
Moderator(s): P. Keane UK
P. Keane UK Use of Swept Source OCT in challenging cases of central serous chorioretinopathy
C. Hoyng Netherlands Morphological and topographical appearance of microaneurysms on Swept-Source OCTA
V. Papastefanou UK Diabetic retinopathy & Swept-Source OCTAngio
A. Gaudric France Topographic variations of choroidal thickness in healthy eyes on Swept-Source optical coherence tomography
Photobiomodulation: An Innovative, Mitochondria-targeted Therapy for Dry AMD and Other Ocular Diseases (An Update)
Moderator(s): J. Eells USA M. Munk Switzerland
J. Eells USA Photobiomodulation for the treatment of retinal and optic nerve disease
K. Valter Australia From bench to bedside – photobiomodulation in preclinical studies (an update)
M. Munk Switzerland LIGHTSITE I: clinical analysis of the safety and efficacy of photobiomodulation in subjects with dry age-related macular degeneration
B. Burton UK LIGHTSITE II: insights from the ongoing multi-center european clinical trial
ILUVIEN for the Prevention of Relapse in Recurrent Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Moderator(s): B. Bodaghi France Q. Nguyen USA
B. Bodaghi France Non-infectious uveitis affecting the posterior segment of the eye
M. Cordero Spain NIU-PS: the unmet patient need
C. Pavesio UK The 001 study: ILUVIEN for the prevention of relapse in recurrent NIU-PS
R. Khoramnia Germany ILUVIEN real world data: experience from clinical practice
Q. Nguyen USA Lessons learned in managing patients with uveitis: avoidance of cumulative damage
Transforming DME Clinical Practice
Moderator(s): A. Loewenstein Israel B. Kuppermann USA
F. Behar-Cohen France
Unravelling the inflammation pathway
A. García-Layana Spain
Seeking consensus in DME management: findings from Spain
L. Kodjikian France
Key questions for managing DME in daily practice
H. Selen Kanar Turkey
Switch on, switch off: case series
Panelists:
A. Loewenstein Israel
B. Kuppermann US
F. Behar-Cohen France
A. García-Layana Spain
L. Kodjikian France
H. Selen Kanar Turkey
Discussion and Q&A
Friday 06 September | 9:45 - 10:45
Morning Symposia
Friday 06 September | 9:45 - 10:45
Keeping a Step Ahead of the Disease: Proactive Treatment for nAMD
Moderator(s): L. Kodjikian France
Welcome and introductions L. Kodjikian France
T&E with Aflibercept: from design to dosing regimen G. Cheung Singapore
Expanding the evidence: T&E in clinical practice P. Kaiser USA
Panel discussion: let's discuss: the practicalities of T&E in the clinic Moderated by: L. Kodjikian France Panelists: G. Cheung Singapore P. Kaiser USA
Summary and close L. Kodjikian France
A New Vision in Retinal Gene Therapy: from Clinical Trials to Clinical Practice
Moderator(s): B. Leroy Belgium J-A. Sahel France
J-A. Sahel France Welcome and introduction
B. Leroy Belgium Starting with the end in mind: understanding the patient experience
M. Pennesi USA Setting the scene: developing a retinal gene therapy for RPE65 mutations
B. Leroy Belgium Patient selection: informing diagnosis through relevant testing
J-A. Sahel France Retinal gene therapy in clinical practice: perspectives from an expert center
B. Leroy Belgium J-A. Sahel France Q&A
B. Leroy Belgium Closing remarks
Seeing the Invisible - Transparent Subthreshold Treatment with Navigated Microsecond Pulsing Laser
Moderator(s): G. Staurenghi Italy
C. Orduna Spain Experiences from 1 year navigated microsecond pulsing laser treatments in DME
N-A. Striebe Germany Navigated microsecond pulsing treatment for central serous chorioretinopathy. A 100 cases review.
E. Di Carlo Germany Short term efficacy and safety of navigated microsecond pulsing laser treatment in patients affected by macular edema after BRVO
J. Chhablani USA Feasibility and study results of navigated microsecond pulsing peripheral laser treatment in diabetic retinopathy
Friday 06 September | 13:00 - 14:00
Lunchtime Symposia
Friday 06 September | 13:00 - 14:00Ranibizumab — Retinal Care For all Ages: RIVAL (nAMD) to RAINBOW (ROP)
Moderator(s): R. Tadayoni France
R. Tadayoni France Welcome
P. Schlottmann Argentina Clinical value of treat & extend regimen and the RIVAL study
A. Koh Singapore Changing clinical paradigm in diabetic retinopathy
N. Eter Germany A new horizon in ROP: the RAINBOW study
Panel Discussion
R. Tadayoni France
Summary and close
Emerging Evidence: Molecular Properties and Patient Outcomes
Moderator(s): F. Behar-Cohen France
Welcome and introductions F. Behar-Cohen France
Design, binding, downstream effect P. Kaiser USA
Could insights into drug dynamics inform patient management? C.X.Y Qian Canada
Consider this: should a stable retina drive the T&E regimen? V. Chaudhary Canada
Panel Discussion: Let’s discuss: how does the evidence inform a proactive approach in clinical practice? Moderated by: P. Kaiser USA Panelists: C.X.Y. Qian Canada V. Chaudhary Canada
Summary of key learnings F. Behar-Cohen France
Breaking the Cycle of Recurrence in DME: Where Research Meets Clinical Practice
Moderator(s): L. Kodjikian France
A. Augustin Germany Inflammatory response and cytokines in DME
P. Udaondo Spain Prognostic and predictive biomarkers: research meets clinical practice
F. Bandello Italy Switch reality: preventing recurrence, preserving vision
Take Another Look: Uncovering New Advances and Future Applications of Ultra-widefield
Moderator(s): T. Peto UK
S. Sadda USA Variability of the normal peripheral choroidal circulation
P. Stanga UK International classification and guidelines for widefield imaging
T. Peto UK Deep learning and artificial intelligence for diagnosing retinal disease
Illuminating the Role of Angiopoietins in Retinal Diseases
Moderator(s): J-F. Korobelnik France
H. Augustin Germany Spotlight on the angiopoietin pathway
J. Monés Spain Clinical evidence for the role of Ang-2 in retinal diseases
New Mirante Multimodal Imaging and OCT-A Analytics Can Help Breakthrough Tricky Cases of Retinal Disorders
Moderator(s): G. Staurenghi Italy
G. Staurenghi Italy The importance of multimodal imaging: the new NIDEK Mirante SLO/OCT platform
T. Ach Germany SD-OCT and OCT-A scans: which, when, and why? Some practical aspects
S. Sadda USA Retro mode imaging in AMD and macular dystrophies
Reimagine your Retina Surgery with Bausch + Lomb
Moderator(s): Y. Le Mer France
R. Carvalho Portugal The power of Stellaris Elite™ - taking performance further
E. Bali Belgium Key learnings and surgical pearls with Vitesse™
Bausch + Lomb R&D team How we’re raising the bar in retina innovation
Saturday 07 September | 9:45 - 10:45
Morning Symposia
Saturday 07 September | 9:45 - 10:45
The Vitreoretinal Procedure - Integration, Stability, Speed
Moderator(s): R. Tadayoni France
R. Tadayoni France Introduction and opening remarks
K. Al Sabti Kuwait Go beyond 3D visualization
F. Devin France Complex and VR surgical cases using the advanced features of the Constellation® Vision System
S. Rizzo Italy Speed, flow, stability, access-the new HyperVit™ 20K vitrectomy Probe
M. Mura Saudi Arabia 27+® as go-to technology for challenging vitreoretinal cases
J.A. Pournaras Switzerland Modern surgical management of vitreoretinal pathologies
N. Bechrakis Germany Management of intraocular tumors with an advanced surgical system
Unsurpassed Vision Gains and Optimized Patient Outcomes in DME
Moderator(s): J-F Korobelnik France
Welcome and introductions J-F. Korobelnik France
Pathogenesis of retinal vascular diseases A. Ambresin Switzerland
Optimizing patient management with early, intensive treatment S. Sivaprasad UK
Aflibercept in the real world: emerging data in DME J-F Korobelnik France
Panel discussion: review of current recommendations and summary of key learnings Moderated by: J-F Korobelnik France
Panelists: A. Ambresin Switzerland
S. Sivaprasad UK
nAMD Management: Beyond the Horizon
Moderator(s): F. Bandello Italy M. de Smet Switzerland
M. De Smet Switzerland
Welcome and introduction
F. Bandello Italy
Unmet needs in the management of nAMD
L. Kodjikian France
What we have learnt about nAMD in the last 15 years
M. Stumpp Switzerland
DARPin® proteins, a new approach
A. García-Layana Spain
What's in the pipeline for patients?
Applying Advanced Digital Technology in Practice
Moderator(s): N. Bressler USA
N. Bressler USA
Chair’s introduction: advanced use of digital technology – examining the potential positive and negative impact on medical practice
A. Loewenstein Israel
Public health need for home monitoring in diabetic retinopathy and age-related macular degeneration
P. Keane UK
Application of deep learning systems for diabetic retinopathy and AMD in clinical practice
N. Bressler USA
The future of clinical trials and clinical practice
Complement C3 Inhibition in Geographic Atrophy
Moderator(s): F.G. Holz Germany
J. Monés Spain
The role of complement in geographic atrophy
U. Chakravaraty UK
Results from the FILLY phase 2 trial
I. Pearse UK
Evaluation of baseline characteristics on GA lesion progression in the FILLY trial
F.G. Holz Germany
Derby and Oaks phase 3 trials in GA
Saturday 07 September | 13:00 - 14:00
Lunchtime Symposia
Saturday 07 September | 13:00 - 14:00New Horizons in nAMD Treatment
Moderator(s): F.G. Holz Germany
F.G. Holz Germany
Welcome and introduction
P. Kaiser USA
Challenges and opportunities in nAMD care
A. Koh Singapore
Moderated panel discussion
R. Hamilton UK
New horizons in nAMD: updates from advanced clinical program
F.G. Holz Germany
Moderated panel discussion
F.G. Holz Germany
Summary and close
Ready for Prime Time: Clinical Evidence of Advances in 27G Surgery
Moderator(s): P. Stalmans Belgium
P. Stalmans Belgium
First evidence for clinical trial of 27G vs 23G surgery
E. El Rayes Egypt
How innovation is making 27G a reality
C. Mazit France
Management of retinal detachment using 27g and a prospective randomised study comparing 25G vs 27G for the management of ERM and macular holes
F. Nerinckx Belgium
First experience with a new shorter 27G vitrectomy kit
Innovative Thinking in Retinal Disease
Moderator(s): J. Seddon USA
A. García-Layana Spain
A. Minnella Italy
How to manage patients at risk of AMD with STARS questionnaire
A. Tufail UK
Artificial intelligence. Where do we go from here?
C. Creuzot-Garcher France
Diabetic retinopathy and OCT-A
D. Crabb UK
And what do people with AMD see?
Management of Retinal Diseases with SubLiminal Laser Therapy
Moderator(s): V. Chong UK
V. Chong UK
How retina lasers are different from each other?
A. Filloy Spain
Fovea-involving DME: reasons for the SubLiminal approach
L. Altay Germany
SubLiminal laser in CCSC management
L. Wu Costa Rica
Why SubLiminal laser should be favored vs PDT for CCSC treatment
V. Chong UK
New treatment perspectives and conclusion
Delivering the Future of nAMD Management
Moderator(s): R. Tadayoni France
A. Loewenstein Israel
Outcomes in real-world settings and therapeutic advancements
P. Campochiaro USA
Continuous delivery: A future approach to nAMD management
Retinal Imaging Advancements
Moderator(s): J-F. Korobelnik France
J-F. Korobelnik France
Exploring new boundaries of OCT-A
G. Staurenghi Italy
Next generation of ultra-widefield angiography
G. Lang Germany
Integrated diagnostic imaging maximizing your diagnostic instruments